ReviewExperimental and therapeutic medicine2021
Epigenetic approaches for cervical neoplasia screening (Review).
Review in Experimental and therapeutic medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- EVX2 methylation assay enables risk assessment of cervical cancer in high-risk HPV-infected individuals.BMC cancer · 2026Article
- Comparative evaluation of microRNA detection in plasma, urine and liquid-based cytology for high-grade cervical intraepithelial neoplasia.Oncology letters · 2026Article
- Review
- Identifying Key Epigenetic Modification-Related Genes for Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma and Cellular Validation.Current gene therapy · 2026Article
- Contemporary Status and Frontiers of Cervical Cancer Screening in the United States.Cancer prevention research (Philadelphia, Pa.) · 2025Review
- Epigenetic Remodeling in Thyroid Cancer: New Dimensions of Targeted Therapy Through lncRNA Modulation.Current issues in molecular biology · 2025Article
- Molecular Insights Into the Natural History of Anal HSIL.Journal of medical virology · 2025Article
- Human papilloma virus (HPV) mediated cancers: an insightful update.Journal of translational medicine · 2025Review
- Combined Effect of Conventional Chemotherapy with Epigenetic Modulators on Glioblastoma.Genes · 2025Article
- Human papillomavirus-mediated cervical cancer: epigenetic interplay and clinical implications.Frontiers in microbiology · 2025Review
- Identification and validation of ferroptosis-related prognostic gene signature in patients with cervical cancer.Translational cancer research · 2024Article
- DNA methylation as a triage tool for cervical cancer screening - A meeting report.Preventive medicine reports · 2024Review
- Cancer/testis-45A1 promotes cervical cancer cell tumorigenesis and drug resistance by activating oncogenic SRC and downstream signaling pathways.Cellular oncology (Dordrecht, Netherlands) · 2024Article
- From Satirical Poems and Invisible Poisons to Radical Surgery and Organized Cervical Cancer Screening-A Historical Outline of Cervical Carcinoma and Its Relation to HPV Infection.Life (Basel, Switzerland) · 2024Review
- PAX1 and SOX1 Gene Methylation as a Detection and Triage Method for Cervical Intraepithelial Neoplasia Diagnosis.Acta cytologica · 2024Article
- Validation of ASCL1 and LHX8 Methylation Analysis as Primary Cervical Cancer Screening Strategy in South African Women with Human Immunodeficiency Virus.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Observational
- Article
- The Role and Applications of Exosomes in Gynecological Cancer: A Review.Cell transplantationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human papillomavirus (HPV) infection is the leading cause of cervical cancer. The Papanicolaou cytology test is the usually employed type of screening for this infection; however, its sensibility is limited. Only a small percentage of women infected with high-risk HPV develop cervical cancer with an array of genetic and epigenetic modifications. Thus, it is necessary to develop rapid, reproducible and minimally invasive technologies for screening. DNA methylation has gained attention as an alternative method for molecular diagnosis and prognosis in HPV infection. The aim of the present review was to highlight the potential of DNA methylation in cervical neoplasia screening for clinical applications. It was observed that the methylation human and viral genes was correlated with high-grade lesions and cancer. Methylation biomarkers have shown a good capacity to discriminate between high-grade lesions with a transformative potential and cervical cancer, being able to detect these modifications at an early stage. With further research, the epigenetic profiles and subtypes of the tumors could be elaborated, which would aid in therapy selection by opening avenues in personalized precision medicine. Response to therapy could also be evaluated through such methods and the accessibility of liquid biopsies would allow a constant monitoring of the patient's status without invasive sampling techniques.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.